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ABSTRACT 
To fabricate donor corneal substitutes based on carbodiimide cross-linked porcine collagen, to study their 
in vitro and in vivo properties, and to elaborate new implantation techniques for the donor corneal 
collagen-based substitutes, this study had been performed. Bioengineered substitutes of corneal stroma 
(BSCS) were fabricated by cross-linking porcine type I collagen with 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide and N-hydroxysuccinimide, as previously described. Their refractive indices were measured 
using an Abbe refractometer. The mechanical properties were evaluated by their ability to tolerate 
interrupted stitches placed during deep lamellar keratoplasty performed on isolated rabbit eyes. BSCS were 
then implanted into one cornea of 8 rabbits and were followed-up for 12 months. Our BSCS had refractive 
indices of 1.24-1.3 (human cornea 1.37-1.38), and tolerated the placement of 12 interrupted stitches well. 
A new technique, the BSCS “stitchless” implantation, was developed. When implanted into rabbit corneas, 
BSCS remained stably integrated and clear during the 12 month follow-up. Non-intensive opacities within 
corneal layers (grade 1.5 on a scale of 0 to 4) were observed in 2/8 eyes during the 1st postoperative week, 
and in one eye the opacity resolved. In the 2nd eye a fine opacity (grade 1) remained. Light microscopy 
confirmed the integrity of the implants and the absence of inflammation in corneal stroma. The current 
data suggest that the BSCS fabricated in the Ukraine by cross-linking collagen is a good alternative to 
human donor corneas if medical grade porcine collagen is used. In addition, the new “stitchless” technique 
of BSCS implantation may decrease corneal substitute damage and accelerate its epithelialisation. 
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INTRODUCTION  
Corneal diseases are a major cause of vision loss, second only 
to cataracts in overall importance, and affect more than 10 
million individuals worldwide [1, 2]. Ocular trauma and corneal 
ulceration due to infection are significant causes of corneal 
blindness that are often underreported but may be responsible 
for 1.5–2.0 million new cases of monocular blindness every 
year [1]. Currently, the only widely accepted corneal blindness 
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treatment is transplantation of a human donor cornea. The 
worldwide demand for transplantation corneas exceeds the 
supply, and this situation will worsen with an aging population 
and the increased use of cornea laser surgery [3].  In 2010, 
there were 2000 individuals waiting for corneal transplantation 
in the Ukraine, but only 357 corneal transplants were 
performed [4].   
Alternatives of human donor cornea used in ophthalmology to 
date include human amniotic membranes [5, 6] and artificial 
substitutes (keratoprosthesis) [7, 8]. However, the use of 
amniotic membrane is limited to corneal ulcer treatments as a 
patch due to its ability to promote healing and it cannot be 
used for optical purposes.  Keratoprostheses are used to 
restore vision in complicated leukomas. Despite some progress 
achieved in this area in recent years, the devices have limited 
indications to their use. Existing prostheses neither integrate 
seamlessly into the host tissue, nor promote reinnervation.  
Recent studies have shown proof-of-concept for the use of 
biomimetic materials as corneal implants to promote corneal 
regeneration as an alternative to donor cornea implantation [9-
11]. Implants were fabricated from carbodiimide cross-linked 
collagen. Their optical, chemical and physical properties were 
similar to human corneas. When used as corneal substitutes for 
transplantation, implants stimulated both corneal tissue and 
nerve regeneration in the experimental animals and patients, 
without the need for immunosuppression.  
However, these early implants had tensile strengths that were 
significantly weaker in comparison to the human cornea [10]. 
That is why the implants were sutured to the recipient cornea 
with overlying stitches in the majority of cases, but not 
continuous or separate ones as in conventional corneal 
transplantation. Overlying sutures may both damage the 
implant and impede implant coverage with corneal epithelium, 
as seen in the clinic study [11]. Interpenetrating networks of 
collagen and phosphorylcholine [12] are more robust, but have 
yet to be tested clinically. 
The purpose of this study was to fabricate donor cornea 
substitutes based on carbodiimide cross-linked porcine 
collagen, to study their in vitro and in vivo properties and to 
elaborate new implantation techniques for the donor cornea 
collagen-based substitutes to prevent possible implant damage 
and delay epithelial coverage. 
 
HYPOTHESES 
Implant fabrication 
Bioengineered substitutes of corneal stroma (BSCS) were 
fabricated by cross-linking porcine type I atelocollagen (Koken, 
Japan) with 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide 
(Sigma-Aldrich, Canada) and N-hydroxysuccinimide (Sigma-
Aldrich, Canada), as previously described [9], collagen 
concentration in gel was 12%. 
Implant testing in vitro 
Refractive indices of the BSCS were measured using an Abbe 
refractometer (Bellingham & Stanley, UK). The mechanical 
properties were evaluated by the ability to tolerate interrupted 
stitches placed during deep lamellar keratoplasty performed on 
isolated rabbit eyes. 
 
Implantation and clinical evaluation 
The study was approved by the Bioethics Committee of the 
Filatov Institute of Eye Diseases and Tissue Therapy. The 
animals were operated on, followed-up and sacrificed under 
the Declaration of Helsinki recommendations for the use of 
animals in experimental studies. BSCS (6mm in diameter) were 
implanted into one cornea of 8 New Zealand rabbits with a new 
“stitchless” technique, and were followed-up for 12 months. 
Animals were only given antibiotics topically 4 times daily 
during the first week after the surgery. No immunosupression 
was used. Stitches were removed at 3 weeks postoperative. 
Follow-ups were performed daily on each animal for up to 7 
days postoperative, and then weekly. Slit-lamp biomicroscopy 
was used to examine the corneas and the BSCS for optical 
clarity, as well as to look for any inflammation (as indicated by 
excessive redness or swelling compared to the un-operated 
contralateral control eye) or neovascularisation. Other tests 
included sodium fluorescein staining to assess epithelial 
integrity and barrier function.  
 
Histopathologic Evaluation  
Animals were sacrificed at 12 months post-implantation. 
Corneas with implants, and control un-operated corneas were 
processed for histopathological examination by light 
microscopy after the sections were stained with H&E 
(Hematoxylin and Eosin stain).   
 
RESULTS 
Testing in vitro 
Almost transparent BSCS (500µm thick) with single, dotty air 
bubble inclusions were fabricated based on the described 
technology (Figure 1).  Our BSCS had refractive indices of 1.24-
1.3 (human cornea 1.37-1.38). The implants were elastic and 
strong enough to tolerate well the placement of 12 interrupted 
stitches during deep lamellar keratoplasty performed on 
isolated rabbit eyes. 
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Figure 1. A collagen-based human donor cornea substitute fabricated at 
the Filatov Institute. 
 
 
Figure 2. Rabbit cornea in different post-implantation terms, (A) 
immediately after surgery, (B) 12 months after surgery, where the BSCS 
is integrated into the host cornea and is visualised because of air 
bubble inclusions only. 
 
Implantation technique and clinical results  
A new “stitchless” implantation method was performed as 
follows: a corneal incision 5mm in length and 4/5 thickness in 
depth was performed with a blade 2mm from the limbus. A 
corneal “pocket” of 7x7mm was then formed with a spatula 
through this incision. The BSCS was implanted in the corneal 
“pocket” with the use of the spatula, and the corneal incision 
was closed with five 9/0 nylon sutures. Superficial corneal 
layers over the BSCS were then removed with 5mm trephine 
(Fig. 2). 
No adverse inflammatory reactions were observed in any of the 
animals. Full epithelial coverage over the BSCS was completed 
within the first five days post-surgery. Neovascularisation 
occurred in the stitch placement area only, and resolved itself 
after the removal of stitches. No neovascularisation was 
observed in the BSCS location area. When implanted into rabbit 
corneas, the BSCS remained stably integrated and clear during 
the 12 month follow-up. Non-intensive opacities within corneal 
layers (grade 1.5 on a scale of 0 to 4) were observed in 2/8 eyes 
during the first postoperative week. In one eye the opacity 
resolved, and a  fine opacity (grade 1) remained in the 2nd eye.  
 
Histopathological Evaluation 
Light microscopy confirmed the good integrity of the implants 
and the absence of inflammation in corneal stroma. The BSCS 
were covered by corneal epithelium, and the cell-free implants 
were populated by corneal stromal cells. At 12 months post-
operative, only a small piece of cell-free BSCS remained in the 
central cornea (Fig. 3). 
 
 
Figure 3. Histology of control and operated corneas at 12 months post-
implantation, (A–B): H&E staining of unoperated (A) and operated 
cornea (B), both showing a stratified epithelium (e) over a stroma (s). A 
small central piece of still cell-free implant (arrow) lies in reconstituted 
corneal stroma (B). Scale bar, 50 µm. 
 
DISCUSSION 
The data of this study confirms the possibility of implant 
fabrication by the carbodiimide cross-linking of porcine medical 
grade collagen, as previously described [9] but we had 
increased the collagen content to approximate the human 
cornea in optical and mechanical properties. The main difficulty 
during the fabrication was air bubble elimination from the 
collagen hydrogel, and this problem is not solved completely. 
Air bubble inclusions may both decrease the vision of potential 
recipients and the implant strength. They may also change the 
refractive index of the latter. It is possible that the implants 
used had slightly lower refractive indices than both normal 
human corneas and previously fabricated implants [9, 12, 13].  
In vivo studies showed that the porcine collagen-based 
substitutes of corneal stroma were well-tolerated, when 
implanted into rabbit corneas, where they were seamlessly 
integrated. The elaborated implantation technique allowed the 
avoidance of implant degradation and neovascularisation in the 
stitch placement areas, as previously noticed [9, 12-14]. It is 
possible that such a technique could prevent a delay in the 
BSCS epithelial closure, which is a problem found in human 
studies as a result of the overlying retaining sutures [11]. The 
tight sutures also appeared to cause irregularities in the surface 
resulting in astigmatism. 
Histological examinations confirmed the good biocompatibility 
of the implants. At 12 months, there was cell overgrowth but 
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stromal cell in-growth was still incomplete in the central-most 
areas. 
 
CONCLUSION 
The current data suggest that the carbodiimide crosslinked 
BSCS fabricated in the Ukraine would most likely be a good 
alternative to human donor corneas if medical grade porcine 
collagen is used and the implants are produced under clinical 
Good Manufacturing practice (cGMP). The new “stitchless” 
technique of implant retention appears to circumvent the 
determental effects of implant compression, neovascularisation 
and prevent delay in the epithelial coverage over the corneal 
substitutes. Further studies will focus on BSCS quality 
improvement and comparisons of different BSCS retention 
techniques. In addition, a phase I clinical study has just started 
to study the efficacy of the porcine collagen-based BSCS 
transplantation for persistent corneal ulcer treatment. 
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